Matinas BioPharma Holdings (MTNB) Capital Expenditures (2013 - 2023)
Matinas BioPharma Holdings (MTNB) reported Capital Expenditures of $16000.0 for Q3 2023, down 93.6% year-over-year from $250000.0 in Q3 2022, and down 61.9% quarter-over-quarter from $42000.0 in Q4 2022.
Matinas BioPharma Holdings (MTNB) Capital Expenditures (2013 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 10 years of Capital Expenditures data on file, last reported at $16000.0 in Q3 2023.
- Capital Expenditures for Q3 2023 came in at $16000.0, down 93.6% year-over-year; the trailing twelve-month figure through Dec 2023 was $308000.0 (down 65.47% YoY), and the FY2023 annual result was $218000.0, down 75.56% from the prior year.
- Capital Expenditures eased to $16000.0 in Q3 2023 per MTNB's latest filing, from $42000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $545000.0 in Q1 2022 and troughed at $5749.0 in Q1 2020.
- A 5-year average of $135516.5 and a median of $48500.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2019 and 2023: Capital Expenditures jumped 100.35% in 2019, then slumped 93.6% in 2023.
- A 5-year view of Capital Expenditures shows it stood at $73430.0 in 2019, then slumped by 92.17% to $5749.0 in 2020, then soared by 522.93% to $35812.0 in 2021, then grew by 17.28% to $42000.0 in 2022, then tumbled by 61.9% to $16000.0 in 2023.
- Business Quant data shows MTNB's Capital Expenditures at $16000.0 in Q3 2023, $42000.0 in Q4 2022, and $250000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 16,000.00 |
| Sep 30, 2023 | 16,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Jun 30, 2022 | 55,000.00 |
| Jun 30, 2022 | 55,000.00 |
| Mar 31, 2022 | 545,000.00 |
| Mar 31, 2022 | 545,000.00 |
| Dec 31, 2021 | 35,812.00 |
| Dec 31, 2021 | 35,812.00 |
| Mar 31, 2020 | 5,749.00 |
| Mar 31, 2020 | 5,749.00 |
| Sep 30, 2019 | 73,430.00 |
| Sep 30, 2019 | 73,430.00 |
| Jun 30, 2019 | 317,928.00 |
| Jun 30, 2019 | 317,928.00 |
| Mar 31, 2019 | 14,246.00 |
| Mar 31, 2019 | 14,246.00 |